Preview of IRADIMED Earnings: Update on Recent Insider Trading, Hedge Fund Activity, and More

IRADIMED is getting ready to announce its quarterly earnings data on October 31st. According to projections from Finnhub, analysts are expecting revenue to reach $20,910,000, with earnings per share at $0.47. For those interested in more detailed information about IRADIMED, it’s worth checking out Quiver Quantitative’s stock page dedicated to IRMD, which tracks insider trading, hedge fund activity, and congressional trading.

When it comes to insider trading at IRADIMED, there have been a total of 14 transactions in the past six months, all on the open market. Surprisingly, the breakdown reveals that none of these transactions were purchases, with all 14 trades being sales. Notably, CEO, President, and Chairman Roger E. Susi has sold 30,000 shares for approximately $2,196,746. Additionally, Monty K. Allen sold 1,102 shares for an estimated $76,148.

Shifting focus to hedge fund activity surrounding IRADIMED, recent data indicates that 77 institutional investors have increased their holdings of IRADIMED stock, while 74 have decreased their positions in the most recent quarter. Noteworthy moves include Millennium Management LLC adding 41,481 shares, representing a 59.1% increase in their portfolio value, and UNIPLAN Investment Counsel, Inc. adding 31,620 shares, a growth of 64.9%. On the other hand, Goldman Sachs Group Inc removed 25,685 shares (15.2%), and Copeland Capital Management, LLC reduced their holdings by 5.3% in the third quarter of 2025.

As for government contracts awarded to IRADIMED, the company has received a total of $315,316 in the last year. Among the significant awards reported are payments for the MRIDIUM MRI Infusion System-Pump and Monitors totaling $192,020, the Non-Magnetic MRI with Accessories and Service Plan for $83,872, and the Non-Magnetic MRI Patient Monitor and Infusion Pump System valued at $39,424. Those interested in tracking government contract payments to publicly traded companies can explore Quiver Quantitative’s government contracts dashboard.

It is important to note that this article does not offer financial advice and recommends referring to Quiver Quantitative’s disclaimers for additional information. Potential inaccuracies could be due to mistakes in ticker-mapping and other anomalies, so exercise caution when interpreting this information.